Padasas Bill Thaddeus, Españo Erica, Kim Sang-Hyun, Song Youngcheon, Lee Chong-Kil, Kim Jeong-Ki
Department of Pharmacy, Korea University College of Pharmacy, Sejong 30019, Korea.
Department of Pharmacy, Sahmyook University, Seoul 01795, Korea.
Immune Netw. 2023 Mar 23;23(2):e13. doi: 10.4110/in.2023.23.e13. eCollection 2023 Apr.
The coronavirus disease 2019 (COVID-19) pandemic is one of the most consequential global health crises in over a century. Since its discovery in 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to mutate into different variants and sublineages, rendering previously potent treatments and vaccines ineffective. With significant strides in clinical and pharmaceutical research, different therapeutic strategies continue to be developed. The currently available treatments can be broadly classified based on their potential targets and molecular mechanisms. Antiviral agents function by disrupting different stages of SARS-CoV-2 infection, while immune-based treatments mainly act on the human inflammatory response responsible for disease severity. In this review, we discuss some of the current treatments for COVID-19, their mode of actions, and their efficacy against variants of concern. This review highlights the need to constantly evaluate COVID-19 treatment strategies to protect high risk populations and fill in the gaps left by vaccination.
2019年冠状病毒病(COVID-19)大流行是一个多世纪以来最严重的全球健康危机之一。自2019年被发现以来,严重急性呼吸综合征冠状病毒2(SARS-CoV-2)不断变异成不同的变体和亚谱系,使先前有效的治疗方法和疫苗失效。随着临床和药物研究的重大进展,不同的治疗策略不断被开发出来。目前可用的治疗方法可根据其潜在靶点和分子机制大致分类。抗病毒药物通过破坏SARS-CoV-2感染的不同阶段发挥作用,而基于免疫的治疗主要作用于导致疾病严重程度的人体炎症反应。在这篇综述中,我们讨论了目前一些针对COVID-19的治疗方法、它们的作用方式以及它们对关注变体的疗效。这篇综述强调了持续评估COVID-19治疗策略以保护高危人群并填补疫苗接种留下的空白的必要性。